Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia.

Trial Profile

Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Zileuton (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 Aug 2011 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top